Pharmaceutical Industry Fellowship Program 2021

NovartisPharmaceutical IndustryFellowship Program 2021Pharmaceutical IndustryFellowship Program 2021Leadership Tradition Motivation Development Dedication

22021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMMessage to Prospective FellowsWhen I started my career as a Post-Doctoral fellow at Novartis, I was seeking a fulfilling career in anuntraditional pharmacy setting. The Rutgers Pharmaceutical Industry Fellowship exposed me to uniqueopportunities, provided me with lifelong mentors, an incredible network of colleagues and allowed me tobuild the foundation for my career in the pharmaceutical industry. Through the years I have remained astrong advocate for the Rutgers Pharmaceutical Industry Fellowship as a key vehicle for acceleratedprofessional development.I can attest that the broad background possessed by a Pharm.D. graduate is highly valued in ourindustry – and certainly here at Novartis. Established in 1990, the Novartis Fellowship is one of thelongest standing programs within the Rutgers family of fellowships with over 200 fellows completing theprogram, signifying its strength and longevity. Each year, we set out to find the “best and the brightest”among the nation’s pharmacy doctoral programs.Novartis fellows consistently demonstrate the drive, self-motivation, and eagerness to learn and succeedwithin the various disciplines we offer, including early clinical development/translational medicine, clinicaldevelopment, regulatory affairs, medical affairs, and commercial strategy/brand marketing.I am enthusiastic about your interest in Novartis and wish you the best of luck during the challenginginterview and application process.Rob Kowalski, Pharm.D.Global Head Regulatory AffairsUS Head DevelopmentNovartisFellow 1993–1995“The broad background possessed by aPharm.D. graduate is highly valued in ourindustry – and certainly here at Novartis.”Rob Kowalski was one of the firstfellows in the original Sandozfellowship program from1993-1995. Rob attended theUniversity of Wisconsin-Madisonwhere he received both a Bachelorof Science in PharmaceuticalSciences and a Doctorate inPharmacy.

32021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsNovartis Company Profile.4Novartis Fellowship Program Overview .9Novartis Fellowship Program Leadership .11Novartis Fellowship Program Fellows.12Novartis Fellowship Program Positions.18Commercial Fellowships .19Global Development Fellowships .21Medical Affairs Fellowships .26Regulatory Affairs Fellowships .30Novartis Fellowship Program Alumni .35Rutgers Pharmaceutical Industry Fellowship .38

42021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsWho We AreOur PurposeWe reimagine medicine to improve and extend people’s lives.We use innovative science and technology to address some of society’s mostchallenging healthcare issues. We discover and develop breakthrough treatmentsand find new ways to deliver them to as many people as possible. We also aim toreward those who invest their money, time and ideas in our company.Our CultureOur aborationPerformanceCourageIntegrityOur Strategic Priorities1Unleash the powerof our people2345Deliver transformativeinnovationGo big on dataand digitalEmbrace operationalexcellenceBuild trust withsociety

52021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsWho We AreOur CompanyInnovative MedicinesThe Innovative Medicines Divisionhas two business units:Novartis OncologyNovartis Oncology focuses onpatented treatments for a variety ofcancers and rare diseases.Novartis PharmaceuticalsNovartis Pharmaceuticals focuses onpatented treatments in multipledisease areas to enhance healthoutcomes to patients and offersolutions to healthcare providers.SandozSandoz offers patients andhealthcare professionals high-quality,affordable generics and biosimilars.Research andDevelopment (R&D)The Novartis Institutes forBiomedical Research (NIBR)is the innovation engine of Novartis.NIBR focuses on discovering new drugsthat can change the practice ofmedicine.Novartis Gene TherapiesFormerly Ave Xis, Novartis GeneTherapies is dedicated to developingand commercializing novel treatmentsfor patients suffering from rare and lifethreatening neurological geneticdiseases.Global Drug Development (GDD)organization oversees the developmentof new medicines discovered by ourresearchers and partners.

62021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsWho We AreOur PeopleOur EthicsThe greatest strength of Novartis is our people, whose diversity,energy and creativity are crucial to our success.Novartis has adopted a single set of ethicalprinciples that should be applied in dailydecision-making by all Novartis associates.Put patientsfirstResearchfor the ES108,775 149ANNUAL TRAININGHOURS PER EMPLOYEEWOMEN INMANAGEMENT35.844%FundresponsiblyAct withclear intent

72021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsNovartis Company ProfileNovartis provides healthcare solutions that address the evolvingneeds of patients and societies worldwide. Our current portfolioincludes more than 50 key marketed products, many of which areleaders in their respective therapeutic areas.Novartis Pharmaceuticals Corporation is headquartered inEast Hanover, New Jersey, which is approximately 40 mileswest of New York City.Novartis Gene Therapies, is headquartered in Bannockburn, ILwith another location in Deerfield, IL. We are dedicated todeveloping and commercializing novel treatments for patientssuffering from rare and life-threatening neurologicalgenetic diseases.Sandoz is located in Princeton, New Jersey. We offer a broad lineof generic medicines – the foundation of global healthcaresystems, but we’re also discovering new ways to improve andextend people’s lives though our innovative off-patent medicines[505(b)(2)], and global leadership in biosimilars.FINANCIAL47.4 bn160 Net sales (USD)Projects in clinicaldevelopment12.9 bnTotal free cash flow (USD)14.1 bnCore operating income (USD)9.1 bnOperating income (USD)11.7 bnNovartis Pipeline2019 Annual ReportKey Performance IndicatorsINNOVATIONNet income (USD)9.4 bnResearch and developmentspend (USD)SOCIAL16 mPatients reached throughaccess programs10 mPeople reached throughhealth education programs1Inconstant currencies and for continuing operations.

82021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsOur Products and ReachWe develop and produce innovative medicines to address patientneeds in disease areas where our experience and knowledge havethe potential to produce transformative YNEUROSCIENCEOPHTHALMOLOGYwhere Novartis products are sold799 mPATIENTSreached in totalINFECTIOUSDISEASESWe offer about 1,000 generic medicines and biosimilars covering majortherapeutic areas. They can bring substantial savings to patients andhealthcare systems and help improve access to healthcare.16 mThrough Novartis Gene Therapies, we are also exploring advancedtherapy platforms such as genes and therapeutic viruses includingAdeno-associated viruses (AAVs) in neuroscience, as well as potentialtreatments for Rett syndrome, a genetic form of amyotrophic lateralsclerosis (ALS), and Friedreich’s ataxia.reached through access programsPATIENTS

92021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsNovartis Fellowship ProgramOur ProgramThe first year of the fellowship is typically dedicated to one of thedepartments described in this brochure. In the second year, fellowshave the option to remain in the same department or transfer toanother group elsewhere within Novartis.Specific fellowship opportunities within departments vary dependingon the interests of prospective candidates as well as the needs ofNovartis. In order to maximize their overall experience and to build asolid skill set, fellows may be presented with the opportunity toparticipate in special projects of interest. Fellows may also attendseminars and workshops designed to build professional skills such astime and project management, negotiation, and developing anddelivering presentations. Opportunities to take internal trainingclasses are also available. Fellows may be eligible to attend medicaland professional conferences where they may present posters,participate in scientific sessions for continuing education credit, andnetwork with colleagues.Novartis fellows have the opportunity to participate in a three-monthrotation either within or outside of Novartis. A broad range ofopportunities are available, including clinical rotations at a universityaffiliated hospital, the Ernest Mario School of Pharmacy, governmentagencies such as the US Food and Drug Administration or theNational Institutes of Health, or other external vendors. Such rotationsare structured to allow fellows to broaden their experience.“The program at Novartis focuses onbuilding a solid foundation with the goal ofmaking a smooth transition to a successfulcareer after the fellowship.”Novartis Second Year Fellows, Fall 2019

102021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAMContentsObjectivesDuring the two-year program at Novartis, the fellow will:§1Gain a comprehensive overview of key areas withinthe pharmaceutical industry through practical insightsand experiences.2§Expand clinical knowledge through participation in bothindustrial and academic programs.3§Promote the role and value of a clinically trainedpharmacist within the pharmaceutical industry.4§Actively participate in specific areas of industry andacademia through direct involvement in various projectsand assignments.5§Become highly marketable for employmentopportunities within the pharmaceutical industry.“Our name, derived from the Latinnovae artes, means “new skills” andreflects our commitment to bringingnew healthcare products to patientsand physicians worldwide.Watch videos to learn more about the program, culture andwhy Novartis is for you:Choosing Novartis for Your FellowshipExperiencing a High Energy CultureBuilding Your Professional Network

112021 NOVARTIS PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM2020–2021 Novartis Fellowship Program LeadershipDirectorsContentsGroup LeadersAngela BrowneCharlene HallChristy SiegelJennifer SladeGlobal Therapeutic Area LeadRegulatory Affairs,Early DevelopmentGlobal Head, Cell & GeneTechnical ServicesVP, RespiratoryFranchise HeadPharm.D.,University of MichiganFellow 2000–2002Pharm.D., Ernest MarioSchool of Pharmacy,Rutgers UniversityFellow 2000–2001Scientific Engagement &Communications Franchise HeadCell & Gene TherapiesKudsia HafeezDaniel CarreonChristopher McBurneyPamela HillGlobal ProgramExecutive DirectorCardio-Renal-MetabolicLead Clinical Trial LeaderTranslational ClinicalOncologyVP, Head of US CAR-TFranchisePharm.D.,Purdue UniversityFellow 2001–2003Pharm.D.,Western University ofHealth SciencesFellow 2010–2012Pharm.D., Universityof ToledoAssociate Director,Global OncologyScientific CommunicationsPharm.D., B.S.,Purdue UniversityFellow 1999–2001Fellowship CoordinatorGinny ManfrediLincy Thomas GeorgeNina KatzSenior AdministrativeAssistantRegulatory AffairsRespiratoryGlobal Therapeutic Area LeadRegulatory Affairs, OncologySenior Global ProgramRegulatory DirectorRegulatory Affairs, OncologyPharm.D., Ernest MarioSchool of Pharmacy,Rutgers UniversityM.B.A., Gabelli School ofBusiness, Fordham UniversityFellow 2003–2005Pharm.D., Ernest MarioSchool of Pharmacy,Rutgers UniversityFellow 2007–2009Pharm.D., Purdue UniversityFellow 2000–2002Pharm.D., St. John’s UniversityFellow 2016–2018The Novartis Fellowship ProgramLeadership Team is comprisedof past fellows that work in partnershipwith preceptors to champion thefellowship experience. The Novartisgroup leaders are additional mentorsthat provide support, guidance andbackground for the fellows to maximizetheir experience at Novartis.